Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | LIPE | Q05469 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 3/20 | 0.38 |
| ▸ | ACACA | Q13085 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522441 | 0.89 | GPR119 (0.41) | CHRM4NAMPTGPR119LIPECYP4F2 | |
| SCHEMBL6520375 | 0.88 | LPL (0.44) | CHRM4NAMPTGPR119LIPECYP4F2 | |
| SCHEMBL6522470 | 0.87 | GPR119 (0.41) | NAMPTGPR119LIPEHPGD | |
| SCHEMBL6525325 | 0.86 | LIPE (0.51) | NAMPTGPR119LIPEPIK3CDPIK3CA | |
| SCHEMBL6525990 | 0.85 | NAMPT (0.46) | NAMPTGPR119LIPE | |
| SCHEMBL6522050 | 0.84 | LNPEP (0.37) | NAMPTGPR119LIPECYP4F2CYP4A11 | |
| SCHEMBL6521594 | 0.84 | NAMPT (0.47) | NAMPTGPR119LIPE | |
| SCHEMBL6523469 | 0.84 | MMP1 (0.49) | NAMPTGPR119LIPE | |
| SCHEMBL6522082 | 0.83 | SRD5A1 (0.41) | NAMPTGPR119LIPE | |
| SCHEMBL6520058 | 0.83 | LIPE (0.57) | NAMPTLIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | CHRM4 1172/4885NAMPT 1696/4885GPR119 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.